A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain

Trial Profile

A Global, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2013

At a glance

  • Drugs Sofinicline (Primary) ; Duloxetine
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 11 Feb 2009 Results reported in a NeuroSearch media release; these results do not support further development of ABT-894 in neuropathic pain, and the pain programme will be discontinued.
    • 10 Nov 2008 Status changed from active, no longer recruiting to completed, as reported in ClinicalTrials.gov record.
    • 30 Oct 2008 Planned end date changed from 1 Sep 2008 to 1 Oct 2008, based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top